Combination Chemotherapy for Hodgkin's Disease
Authors: FRED P. ROSENFELT
Journal: Annals of Internal Medicine (1985)

Letters and Corrections1 April 1985Combination Chemotherapy for Hodgkin's DiseaseFRED P. ROSENFELT, M.D.FRED P. ROSENFELT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-4-554_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Harker and colleagues (1) recently reported their results with second-line therapy of Hodgkin's disease resistant to treatment with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP). Their retrospective review failed to show significant differences in response rates or survival for patients treated with either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or bleomycin, lomustine, doxorubicin, and vinblastine (B-CAVe). The authors conclude that the 20% 5-year survival rate of their patients supports the need for new treatment approaches.Harker and colleagues failed to comment, however, on the fact that these two treatment protocols contain three of the same drugs (doxorubicin, bleomycin,...References1. HARKERKUSHLANROSENBERG WPS. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984;101:440-6. LinkGoogle Scholar2. MEADHARKERKUSHLANROSENBERG GWPS. Single agent palliative chemotherapy for end-stage Hodgkin's disease. Cancer. 1982;50:829-35. CrossrefMedlineGoogle Scholar3. HANSENSELAWRYPAJAK HOT. The superiority of CCNU in the treatment of advanced Hodgkin's disease. Cancer. 1981;47:14-8. CrossrefMedlineGoogle Scholar4. FREILUCETALLEY EJR. DTIC in the treatment of lymphoma. Cancer Chemother Rep. 1974;56:667-70. Google Scholar1. PORZIGPORTLOCKROBERTSONROSENBERG KCAS. Treatment of advanced Hodgkin's disease with B-CAVe following MOPP failure. Cancer. 1978;41:1670-5. CrossrefMedlineGoogle Scholar2. KRIKORIANPORTLOCKROSENBERG JCS. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978;41:2107-11. CrossrefMedlineGoogle Scholar3. SCHABELSKIPPERTRADERLASTERGRISWOLDCORBETT FHMWDT. Establishment of cross-resistant profiles for new agents. Cancer Treat Rep. 1983;67:905-22. MedlineGoogle Scholar4. BECKMUELLERTANZER WTL. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979;39:2070-6. MedlineGoogle Scholar5. HARKERSTEWARTSIKIC WSB. Multidrug resistance in doxorubicin-selected variants of the human sarcoma cell line, MES-SA. Cancer Res. 1985. (In press). MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cedars-Sinai Medical Center Los Angeles, CA 90048 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1985Volume 102, Issue 4Page: 554-555KeywordsCombination chemotherapyDrugsHodgkin lymphomaMechlorethamineProcarbazine Issue Published: 1 April 1985 PDF DownloadLoading ...